Developmental neuroscience

AMO Pharma Reports Positive Data from Investigator-Led TIDE Study of AMO-02 in Autism Spectrum Disorder

Retrieved on: 
Monday, October 29, 2018
Psychiatry, Psychiatric diagnosis, Neuroscience, Health, Autism, Developmental neuroscience, Neurological disorders, Pervasive developmental disorders, Developmental disorder, Neurodevelopmental disorder, Spectrum disorder, Outline of autism

Autism spectrum disorder (ASD) is a common neurodevelopmental disorder, characterized by social deficits and repetitive behaviors.

Key Points: 
  • Autism spectrum disorder (ASD) is a common neurodevelopmental disorder, characterized by social deficits and repetitive behaviors.
  • "AMO Pharma would like to thank Dr. Anagnostou, the POND network and the families that took part in this study."
  • NIMH defines Autism Spectrum Disorder as: "Autism spectrum disorder (ASD) is a developmental disorder that affects communication and behavior.
  • Although ASD can be a lifelong disorder, treatments and services can improve a person's symptoms and ability to function.

Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types

Retrieved on: 
Sunday, October 21, 2018
Tyrosine kinase receptors, Cancer, RTT, Developmental neuroscience, Chemistry, Entrectinib, Biology, Organic chemistry

This is the only analysis to examine the efficacy and safety of a single-purpose drug for the treatment of TRK fusion cancer.

Key Points: 
  • This is the only analysis to examine the efficacy and safety of a single-purpose drug for the treatment of TRK fusion cancer.
  • "These data from a large patient group with TRK fusion cancer are truly encouraging bringing us one step further to delivering this treatment to patients," said Dr. Scott Z.
  • "We look forward to bringing this potential treatment option to adults and children with TRK fusion cancer as soon as possible."
  • Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach.

Shining a Light on Depression - How Infrared Light Can Treat Depression

Retrieved on: 
Monday, October 8, 2018
Neurotrophic factors, Biology, Neuroscience, Biochemistry, Developmental neuroscience, Growth factors, Peptide hormones, Animal anatomy, Brain

Using a unique, high-powered, multi-Watt near-infrared light (NILT), they have shown significant treatment benefit in many patients.

Key Points: 
  • Using a unique, high-powered, multi-Watt near-infrared light (NILT), they have shown significant treatment benefit in many patients.
  • The non-invasive infrared light can safely penetrate the scalp and skull, reaching the brain to re-energize damaged brain cells and activate the brain's own healing processes.
  • "Infrared light delivered properly, can activate brain-derived neurotrophic factor or BDNF," Dr. Henderson explained to the doctors and audience of The Doctors Show .
  • NILT induces regeneration processes and reduces inflammation in the brain and this has proven an effective treatment of depression.

Intravenous Immunoglobulin (IVIg) Treatment May Benefit Some Children with Autism Spectrum Disorder

Retrieved on: 
Wednesday, September 12, 2018
Medicine, Psychiatric diagnosis, Developmental neuroscience, Health, Psychiatry, Neurological disorders, RTT, Developmental psychology, Autism, Neurodevelopmental disorder, Developmental disorder, Immunoglobulin therapy

OKLAHOMA CITY, Sept. 12, 2018 /PRNewswire/ --A subset of children with autism spectrum disorder (ASD), who have an immune abnormality, may benefit from intravenous immunoglobulin (IVIg) treatment, according to new research from Richard E. Frye, MD, PhD, Chief of Neurodevelopmental Disorders at the Barrow Neurological Institute at Phoenix Children's Hospital.

Key Points: 
  • OKLAHOMA CITY, Sept. 12, 2018 /PRNewswire/ --A subset of children with autism spectrum disorder (ASD), who have an immune abnormality, may benefit from intravenous immunoglobulin (IVIg) treatment, according to new research from Richard E. Frye, MD, PhD, Chief of Neurodevelopmental Disorders at the Barrow Neurological Institute at Phoenix Children's Hospital.
  • According to Dr. Frye and colleagues, this is the largest case series examining children with ASD who have been treated with IVIg.
  • The article "Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism" is published in the August issue of Translational Psychiatry.
  • Recent studies have shown that some children with autism spectrum disorder have an immune system dysfunction.

Intravenous Immunoglobulin (IVIg) Treatment May Benefit Some Children with Autism Spectrum Disorder

Retrieved on: 
Wednesday, September 12, 2018
Medicine, Psychiatric diagnosis, Developmental neuroscience, Health, Psychiatry, Neurological disorders, RTT, Developmental psychology, Autism, Neurodevelopmental disorder, Developmental disorder, Immunoglobulin therapy

OKLAHOMA CITY, Sept. 12, 2018 /PRNewswire/ --A subset of children with autism spectrum disorder (ASD), who have an immune abnormality, may benefit from intravenous immunoglobulin (IVIg) treatment, according to new research from Richard E. Frye, MD, PhD, Chief of Neurodevelopmental Disorders at the Barrow Neurological Institute at Phoenix Children's Hospital.

Key Points: 
  • OKLAHOMA CITY, Sept. 12, 2018 /PRNewswire/ --A subset of children with autism spectrum disorder (ASD), who have an immune abnormality, may benefit from intravenous immunoglobulin (IVIg) treatment, according to new research from Richard E. Frye, MD, PhD, Chief of Neurodevelopmental Disorders at the Barrow Neurological Institute at Phoenix Children's Hospital.
  • According to Dr. Frye and colleagues, this is the largest case series examining children with ASD who have been treated with IVIg.
  • The article "Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism" is published in the August issue of Translational Psychiatry.
  • Recent studies have shown that some children with autism spectrum disorder have an immune system dysfunction.

Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

Retrieved on: 
Thursday, August 23, 2018
Neurotrophic factors, Biology, Cell biology, Cell signaling, Neurochemistry, Developmental neuroscience, Cenegermin, Proteins, Neurotrophic keratitis, Nerve growth factor, Low-affinity nerve growth factor receptor, Neurotrophic factor receptor

"Oxervate represents the first therapy from Domp that will be available in the United States," said Sergio Domp, Chairman of Domp.

Key Points: 
  • "Oxervate represents the first therapy from Domp that will be available in the United States," said Sergio Domp, Chairman of Domp.
  • It contains cenegermin-bkbj, a recombinant form of human nerve growth factor, a protein made by the human body.
  • Nerve growth factor (NGF) acts through specific high-affinity and low-affinity nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.
  • Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.

Neurim Pharmaceuticals Receives Positive CHMP Opinion for Slenyto (Pediatric Prolonged-Release Melatonin) for the Treatment of Insomnia in Children With Autism Spectrum Disorder (ASD)

Retrieved on: 
Monday, July 30, 2018
Autism, Psychiatry, Abnormal psychology, Psychiatric diagnosis, Learning disabilities, Neuroscience, Autism spectrum, Developmental neuroscience, Developmental psychology

"The positive CHMP opinion of our PedPRM formulation represents a significant milestone in addressing an unmet need for ASD children who suffer severely from impaired sleep.

Key Points: 
  • "The positive CHMP opinion of our PedPRM formulation represents a significant milestone in addressing an unmet need for ASD children who suffer severely from impaired sleep.
  • Adjusting the dosage according to individual response was easy and the formulation was exceptionally well tolerated in this population.
  • Related measures of children's daytime mood and behaviours also improve with this treatment, as does the parental quality of life.
  • The treatment will address a significant need in the medical management of some children and adolescents with autistic spectrum disorders."

BrainStorm Announces Grant of a New European Patent for NurOwn®

Retrieved on: 
Wednesday, July 25, 2018
Biology, Developmental neuroscience, Neurotrophic factors, Peptide hormones, Stem cells, Brain-derived neurotrophic factor, Amyotrophic lateral sclerosis, Mesenchymal stem cell, Amyotrophic lateral sclerosis research

This patent provides protection for NurOwn in Europe until 2029.

Key Points: 
  • This patent provides protection for NurOwn in Europe until 2029.
  • The allowed claims cover methods of treating amyotrophic lateral sclerosis (ALS) using mesenchymal stem cells that secrete neurotrophic factors, including Brain derived neurotrophic factor (BDNF).
  • The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.
  • NurOwn has been administered to over 70 patients with ALS in clinical trials conducted in the United States and Israel.

Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting

Retrieved on: 
Monday, July 2, 2018
Biology, Cell biology, Cell signaling, Developmental neuroscience, Growth factors, Neurotrophic factors, Peptide hormones, Brain-derived neurotrophic factor, NMDA receptor, Synaptogenesis, Insulin-like growth factor 1, MTOR

This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.

Key Points: 
  • This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.
  • The data indicate that PKC's synaptogenesis efficacy cannot occur when the NMDA receptor is blocked.
  • We are excited to be presenting this new data at this prestigious international forum" stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.
  • Clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share the Company's views of the Phase 2 data.

Scientists Learn More about How Gene Linked to Autism Affects Brain

Retrieved on: 
Monday, June 18, 2018
Psychiatry, Psychiatric diagnosis, Neuroscience, Abnormal psychology, Autism, Developmental neuroscience, Developmental psychology, Pervasive developmental disorders, Heritability of autism, Causes of autism

Scientists at Cincinnati Children's Hospital Medical Center report in Developmental Cell their data clarify the biological role of the gene CHD8 and its protein CHD8 in developing oligodendrocytes, cells that form a protective insulation around nerves.

Key Points: 
  • Scientists at Cincinnati Children's Hospital Medical Center report in Developmental Cell their data clarify the biological role of the gene CHD8 and its protein CHD8 in developing oligodendrocytes, cells that form a protective insulation around nerves.
  • The sheath supports neuronal connections in the brain and manifest themselves in white matter.
  • Although previous studies show disruptive mutations in CHD8 cause autism spectrum disorders (ASDs) and abnormalities in the brain's white matter, the underlying biology has been a mystery.
  • "So far no treatment is available for autism patients with mutations in CHD8, one of the highest risk-susceptibility genes for autism," Lu said.